Topic

healthspan

3 articles on healthspan in longevity medicine. View all news →

Sex-specific longitudinal reversal of aging in old frail mice

Oxytocin plus ALK5 Inhibition in Old Mice: What 73% Means

A late-life oxytocin and ALK5-inhibitor experiment extended remaining survival in male mice, but not females. Here is what the 73% result does and does not mean.

oxytocin TGF-beta aging-research
ARPA-H PROSPR program

ARPA-H PROSPR in 2026: Seven Awards, $144M, and What Has Not Been Proven Yet

ARPA-H's PROSPR program funds seven teams with up to $144 million. Here is what the program is testing, what its milestones mean, and why it is not yet validation of a healthspan treatment.

ARPA-H healthspan clinical trials
UT Health San Antonio

UT Health Rapamycin Study: Three Sub-Studies, Two Timelines, and No Results Yet

UT Health San Antonio described a multi-phase rapamycin project and a separate short recruitment study. Here is what each protocol tests, what remains unknown, and what the announcement does not prove.

rapamycin mTOR inhibitors clinical trials